Esco Healthcare

If you look closely, global aseptic frameworks are more aligned than they first appeared. Across guidance from the U.S. Food and Drug Administration, European Medicines Agency, World Health Organization, and Pharmaceutical Inspection Co-operation Scheme, there is a consistent scientific foundation: - Human intervention remains a primary contamination risk  - Contamination control should be science- and risk-based  - Barrier technologies are widely recognized as effective mitigation strategies   In fact, industry guidance consistently emphasizes the role of separative technologies such as isolators and RABS in reducing contamination risk from operators.  At the same time, differences emerge, not in what needs to be achieved, but in how it is demonstrated. Some frameworks are more prescriptive.  Others rely more on performance-based justification. For manufacturers, this means navigating both science and interpretation. If you want a structured comparison of how these expectations apply specifically to aseptic barrier systems (isolators and RABS), we’ve compiled it here: https://lnkd.in/gbRMGMkr #AsepticProcessing #ContaminationControlStrategy #IsolatorTechnology #SterilityAssurance #PharmaEngineering #GMPCompliance #RegulatoryAlignment #CleanroomTechnology #PharmaQuality #RiskBasedApproach 

Within the complexity of GPPI configurations, pressure and airflow are two parameters that consistently come up in containment strategy discussions. They directly influence the direction of contaminant flow and define protection priorities. Which pressure and airflow configuration fits best? The answer isn’t one-size-fits-all. It depends on how the contamination control strategy is defined, how the risk assessment is structured, what the application demands, and how far the facility infrastructure can support it. Because in the end, selecting pressure and airflow isn’t just a configuration decision, it reflects how well the system is designed to manage risk. Check here for common approaches to selecting pressure and airflow for GPPI. Learn more: https://lnkd.in/eB75e4vt #EscoLifesciences #GPPI #EscoIsolator

Grateful for the connections and conversations at INTERPHEX 2026. Thank you to everyone who stopped by Booth 2805. Your time, insights, and shared perspectives made this event truly meaningful for us. It was a pleasure exploring how Esco Lifesciences can support your manufacturing goals with tailored solutions that drive efficiency, compliance, and innovation. We look forward to continuing these conversations and building lasting partnerships beyond the show.

Thank you to everyone who visited us at Making Pharmaceuticals 2026 It was a pleasure connecting with industry professionals and having insightful discussions on practical, engineering-led solutions for pharmaceutical manufacturing. We truly appreciate the strong interest in our tailored solutions designed to support your specific operational needs. A special thank you to those who took the time to meet with our colleague Paul Bridgman and Tom Richards. We hope you found the conversations valuable. If we didn’t get the chance to speak during the event, feel free to reach out! We’d be happy to continue the conversation. #EscoLifesciences #MakingPharma2026

Aseptic manufacturing is one of the most tightly controlled areas in pharmaceutical production. But in reality, manufacturers rarely operate under just one framework.  A single process may need to meet expectations from the U.S. Food and Drug Administration, European Medicines Agency, World Health Organization, and Pharmaceutical Inspection Co-operation Scheme, each with its own structure, terminology, and level of detail. The objective is consistent:  → ensure sterility and protect patients But the way that objective is defined, documented, and assessed can differ.  Same facility. Same process. Different regulatory lenses. This raises an important question:  Is global aseptic manufacturing truly harmonized, or are we aligning outcomes while navigating different expectations? If you're working with isolators or RABS, this becomes even more relevant.  To explore this deeper, we recently developed a white paper on global regulatory harmonization across FDA, EMA, PIC/S, and WHO, specifically focused on aseptic barrier systems: https://lnkd.in/gbRMGMkr In the next post, let’s break down where these frameworks genuinely align and where interpretation begins to diverge. #AsepticManufacturing #SterileProcessing #PharmaManufacturing #GMP #Annex1 #ContaminationControl #RegulatoryScience #PharmaCompliance #Cleanroom #PharmaceuticalIndustry 

No final sterilization means no room for error. While terminal sterilization remains the preferred method for sterility assurance, it is not feasible for many modern therapies and may damage their structure and function. Advanced products such as mRNA, ADCs, vaccines, and cell & gene therapies are highly sensitive, requiring alternative approaches to achieve sterility without compromising product quality. Aseptic processing becomes essential, where every stage, from pre-sterilization to final assembly, must be tightly controlled to prevent contamination. To meet these demands, Esco GPPI is engineered to deliver a Grade A / ISO Class 5 environment, ensuring a high level of contamination control for critical processes while offering the flexibility to adapt to your facility requirements. Download the brochure to explore Esco GPPI in detail: https://lnkd.in/guPSkCxH #EscoLifesciences #GPPI #EscoIsolator

Countdown to INTERPHEX 2026 📅 April 21–23, 2026 📍 Javits Center, New York City 📌 Booth 2805 We’re heading to INTERPHEX to showcase how we support your workflow across the full spectrum—from containment solutions to aseptic processing systems designed for compliance, reliability, and performance. 🇺🇸 Proudly made in the USA, backed by local engineering and manufacturing expertise. Built with compliance at the core. Meet our team on-site, including Ryan Clayton Anthony Paone @Tyler Denike Dave Mitchell, and connect with us to discuss how we can support your operations with practical, scalable solutions. We look forward to seeing you in New York. #EscoLifesciences #INTERPHEX2026

We’re excited to announce that we will be exhibiting at Making Pharmaceuticals 2026, one of the UK’s key events dedicated to practical, engineering-led solutions in pharmaceutical manufacturing. Date: 21–22 April 2026 Venue: Coventry Building Society Arena Booth: Stand 618 Join us to discover how we deliver tailored solutions designed to meet your specific manufacturing needs, supporting efficiency, compliance, and innovation on the production floor. Our colleague Paul Bridgman will be there and looks forward to connecting with you, feel free to stop by for a conversation. #MakingPharmaceuticals #PharmaManufacturing #LifeSciences #Exhibition #UKEvents

Is Your Choice of Barrier Technology Truly Annex 1 Compliant? The latest 2022 revision of EU GMP Annex 1 has fundamentally changed how we view aseptic processing. The choice between RABS and isolator technology is no longer a simple matter of capital expenditure, but a strategic decision centered on Quality Risk Management (QRM) and Contamination Control Strategy (CCS). Every facility possesses a unique risk profile; therefore, the selected technology must be capable of mitigating those specific risks. In our latest article, we break down:  - The scope of Annex 1 for sterile medicinal products.  - A technical comparison of barrier technologies for aseptic processing.  - A risk-based decision framework to help you select the right system for your facility. By basing this choice on a profound risk assessment, manufacturers do more than just ensure compliance with Annex 1 regulations. They guarantee the highest quality and efficacy for medicinal products, and most importantly, uphold patient safety. Read our full article here: https://lnkd.in/gmPpDpAv #Annex1 #AsepticProcessing #QualityRiskManagement #GMPCompliance